New York lawmakers are advancing the Beauty Justice Act, one of the most comprehensive state-level efforts in the country to regulate cosmetics and personal care products. For in-house counsel at cosmetics and personal care companies, the bill is worth tracking now because it could affect product formulation, supplier oversight, labeling, and litigation risk well before any compliance deadline. The bill responds to growing concerns over consumer exposure to chemicals linked to cancer, hormone disruption, reproductive harm, allergies, and other health risks. Supporters argue that current federal law, including the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), does not go far enough. Framed as both a public health and environmental justice measure, the legislation aims to protect consumers in vulnerable communities disproportionately exposed to these products.
-
Background
The Beauty Justice Act remains pending before the New York Legislature; if enacted, its core product restrictions would apply beginning January 1, 2029. The bill would prohibit cosmetics and personal care products sold in New York from containing intentionally added chemicals on the bill’s restricted substances list. It would also require companies to evaluate whether ingredients listed as “fragrance,” “flavor,” “colorant,” or other functional classifications contain restricted chemicals, comply with contaminant thresholds such as lead limits, and monitor Department of Environmental Conservation (DEC) rulemaking that may add substances to the restricted list over time. The bill targets numerous chemicals that have already faced scrutiny in other jurisdictions and regulatory frameworks, including per- and polyfluoroalkyl substances (PFAS), parabens, phthalates, certain dyes, and preservatives.
Compliance would not be limited to checking ingredient labels against a static list. Companies would need to account for restricted substances captured within broader ingredient categories and monitor future rulemaking, while recognizing that the proposal excludes unintentionally added elements or compounds and incidental byproducts resulting from the breakdown of added elements or compounds.
-
Enforcement and Litigation Risk
The bill would make the following conduct actionable through statutory enforcement, daily civil penalties, and injunctive relief. Those same statutory hooks could also support private litigation theories. Violations may arise from:
- Selling, offering for sale, or distributing noncompliant products in New York.
- Failing to disclose or accurately classify intentionally added ingredients, including those captured by functional categories.
- Exceeding contaminant thresholds, including lead limits as they evolve.
- Continuing to sell products containing substances added to the restricted list through future rulemaking.
Retailers may rely on manufacturer certificates of compliance when assessing whether products meet the bill’s requirements, but a false certificate would itself constitute a violation. The statute would authorize civil penalties of $1,000 per day for a first violation and $2,500 per day for subsequent violations, along with injunctive relief. Because the same facts — intentional ingredient use, contaminant levels, labeling disclosures, and certification practices — could be used by private plaintiffs, the bill may also invite consumer fraud, false advertising, toxic exposure, and product liability claims.
-
What In-House Counsel Should Do Now
In-house counsel should treat the Beauty Justice Act as a near-term regulatory and litigation risk rather than a speculative proposal. Legal teams advising manufacturers, retailers, and other industry participants should consider the following steps now:
- Coordinate a cross-functional ingredient audit across all SKUs sold in New York, including intentionally added ingredients and possible contaminants.
- Work with procurement, regulatory, and quality teams to map upstream sources of restricted substances, including fragrance houses and contract manufacturers.
- Pressure-test reformulation, product discontinuation, and sell-through timelines, given long production lead times and the anticipated 2029 compliance deadline.
- Assign responsibility for monitoring future DEC rulemaking, which may materially expand the restricted substances list.
- Review supplier certifications, labeling, marketing claims, and risk disclosures to reduce enforcement and private litigation exposure.
Conclusion
In-house counsel should view the proposal as an enterprise compliance issue that will reach product development, supplier management, labeling, and claims review. The key takeaway is that the bill would be both a compliance and litigation-risk issue, not merely a product-reformulation project. Legal teams should begin coordinating with regulatory, R&D, quality, supply chain, and marketing stakeholders before enactment.
The material contained in this communication is informational, general in nature and does not constitute legal advice. The material contained in this communication should not be relied upon or used without consulting a lawyer to consider your specific circumstances. This communication was published on the date specified and may not include any changes in the topics, laws, rules or regulations covered. Receipt of this communication does not establish an attorney-client relationship. In some jurisdictions, this communication may be considered attorney advertising.
